Skip to main content

#125 Nicotinamide Adenine Dinucleotide (NAD) Clinical Updates

Current Status

Not Enrolled

Price

$59

Get Started

#125 Nicotinamide Adenine Dinucleotide (NAD) Clinical Updates

1.5 CE Total | 1.5 Pharm

This course is now accredited through AANP starting March 13th, 2026

Washington State ND’s: This CME is co-accredited by WANP which allows WA State Category-1 CME Credit for WA Licensed ND’s

Abstract:

NAD Pharmacology has become more commonly included in therapeutic interventions in the past decade. Direct (parenteral) applications via IV and IM routes have seen increased use and oral “NAD Support” protocols via niacinamide, NR, NMN and others have also seen great interest. This CME is designed to update the clinician in all the relevant areas around the augmentation of NAD function, safety issues, and uses of oral and parenteral agents in doing so.

Learning Objective:

  • Describe the biochemistry of NAD in the human
  • Describe the pharmacology of NAD and precursors
    • Niacinamide
    • Nicotinamide Riboside (NR)
    • Nicotinamide Adenine Dinucleotide (NADH)
    • Nicotinamide Mononucleotide (NMN)
  • Describe the common oral NAD supports and their limitations
    • Niacinamide
    • Nicotinamide Riboside (NR)
    • Nicotinamide Adenine Dinucleotide (NADH)
    • Nicotinamide Mononucleotide (NMN)
  • Describe the use of parenteral (IV /IM) NAD drugs
    • Niacinamide
    • Nicotinamide Riboside (NR)
    • NAD+
    • Nicotinamide Adenine Dinucleotide (NADH) – historical information
  • Discuss safety aspects of all mentioned interventions

Course Content

#125 NAD Clinical Updates Recording
#125 NAD Updates CE Quiz

9 Comments

Leave a Reply